Status: Recruiting
To Observe the Dual-target Chimeric Antigen Receptor T Cells in the Treatment of B Cell Hematologic Tumors
To observe the long-term efficacy and safety of dual-target chimeric antigen receptor T cells in the treatment of refractory relapsed B cell hematologic tumors (at least 2 years).
Participants needed: 100
Trial details
Phase: Phase 1Age: 18-70Biological sex: AllType: InterventionalSponsor: Hebei Senlang Biotechnology Inc., Ltd.Updated: Jun 18, 2025Locations: 1
Eligibility criteria
Refractory and relapsed B-cell tumor determined by clinical diagnosis, B cell tu... [+1]
With other diseases that are not effectively controlled, including, but not limi... [+9]